Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and Clostridium difficile infection.

Evaluation of the US Food and Drug Administration sentinel analysis tools in confirming previously observed drug-outcome associations: The case of clindamycin and Clostridium difficile infection. Pharmacoepidemiol Drug Saf. 2018 07; 27(7):731-739.

View in: PubMed

subject areas

Adverse Drug Reaction Reporting Systems
Anti-Bacterial Agents
Clindamycin
Clostridium Infections
Humans
Risk Factors
Sentinel Surveillance
United States
United States Food and Drug Administration